These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 12780556)
21. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients. Khan MT; Hamid RB; Sarfaraz S; Lal N; Ahmed J; Luxmi S Saudi J Kidney Dis Transpl; 2020; 31(6):1432-1438. PubMed ID: 33565460 [TBL] [Abstract][Full Text] [Related]
22. Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient. Al-Uzri AY; Seltz B; Yorgin PD; Spier CM; Andreoni K Pediatr Transplant; 2002 Apr; 6(2):161-5. PubMed ID: 12000474 [TBL] [Abstract][Full Text] [Related]
23. Different responses of human anti-HLA and anti-alphagal antibody to long-term intravenous immunoglobulin therapy. Bühler L; Pidwell D; Dowling RD; Newman D; Awwad M; Cooper DK Xenotransplantation; 1999 Aug; 6(3):181-6. PubMed ID: 10503784 [TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Jordan SC; Tyan D; Czer L; Toyoda M Pediatr Transplant; 1998 May; 2(2):92-105. PubMed ID: 10082441 [TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Tyan DB; Li VA; Czer L; Trento A; Jordan SC Transplantation; 1994 Feb; 57(4):553-62. PubMed ID: 8116041 [TBL] [Abstract][Full Text] [Related]
26. [Impact of anti-HLA antibodies on renal transplantation]. Tanabe K Nihon Jinzo Gakkai Shi; 2008; 50(7):875-9. PubMed ID: 19069143 [No Abstract] [Full Text] [Related]
27. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Jordan SC; Quartel AW; Czer LS; Admon D; Chen G; Fishbein MC; Schwieger J; Steiner RW; Davis C; Tyan DB Transplantation; 1998 Sep; 66(6):800-5. PubMed ID: 9771846 [TBL] [Abstract][Full Text] [Related]
28. [Desensitization protocols in immunized living donor kidney transplant recipients]. Nocera A G Ital Nefrol; 2009; 26(4):499-515. PubMed ID: 19644839 [TBL] [Abstract][Full Text] [Related]
29. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502 [TBL] [Abstract][Full Text] [Related]
30. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Kozlowski T; Andreoni K Ann Transplant; 2011; 16(2):19-25. PubMed ID: 21716181 [TBL] [Abstract][Full Text] [Related]
31. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Appel JZ; Hartwig MG; Davis RD; Reinsmoen NL Hum Immunol; 2005 Apr; 66(4):378-86. PubMed ID: 15866701 [TBL] [Abstract][Full Text] [Related]
33. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Jordan SC; Vo A; Tyan D; Toyota M Trans Am Clin Climatol Assoc; 2006; 117():199-211; discussion 211. PubMed ID: 18528474 [TBL] [Abstract][Full Text] [Related]
34. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Lefaucheur C; Nochy D; Andrade J; Verine J; Gautreau C; Charron D; Hill GS; Glotz D; Suberbielle-Boissel C Am J Transplant; 2009 May; 9(5):1099-107. PubMed ID: 19422335 [TBL] [Abstract][Full Text] [Related]
36. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617 [TBL] [Abstract][Full Text] [Related]
37. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible? Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064 [TBL] [Abstract][Full Text] [Related]
38. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Anglicheau D; Loupy A; Suberbielle C; Zuber J; Patey N; Noël LH; Cavalcanti R; Le Quintrec M; Audat F; Méjean A; Martinez F; Mamzer-Bruneel MF; Thervet E; Legendre C Am J Transplant; 2007 May; 7(5):1185-92. PubMed ID: 17359509 [TBL] [Abstract][Full Text] [Related]
39. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
40. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Jordan SC; Toyoda M; Vo AA Expert Rev Clin Immunol; 2011 May; 7(3):341-8. PubMed ID: 21595600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]